



^a Depending on the test used, the window period may be shorter than 6 weeks. Clinicians should contact appropriate laboratory authorities to determine the window period for the test that is being used.

^b If the source is known to be HIV-infected, information about his/her viral load, ART medication history, and history of antiretroviral drug resistance should be obtained when possible to assist in selection of a PEP regimen.²³ **Initiation of the first dose of PEP should not be delayed while awaiting this information and/or results of resistance testing.** When this information becomes available, the PEP regimen may be changed if needed in consultation with an experienced provider.

^c See Appendix A for dosing recommendations in patients with renal impairment.

^d Lamivudine 300 mg PO qd may be substituted for emtricitabine. A fixed-dose combination is available when tenofovir is used with emtricitabine (Truvada 1 PO qd).

^e See Appendix A for drug-drug interactions, dosing adjustments, and contraindications associated with raltegravir and dolutegravir.